Aastrom Enrolls First Patients In Phase 2b Clinical Trial of Ixmyelocel-T
Aastrom Biosciences Inc. (Nasdaq:ASTM), the developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patients have been enrolled in the ixCELL-DCM clinical trial.
